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OBJECTIVES: To determine the roles of body size and longitudinal body weight changes in the survival of
incident peritoneal dialysis patients.
PATIENTS ANDMETHODS: Patients (n = 1911) older than 18 years of age recruited from 114 dialysis centers (Dec/
2004-Oct/2007) and participating in the Brazilian Peritoneal Dialysis Multicenter Cohort Study were included.
Clinical and laboratory data were collected monthly (except if the patient received a transplant, recovered renal
function, was transferred to hemodialysis, or died).
RESULTS: Survival analyses were performed using Kaplan-Meier survival curves and Cox proportional hazards.
Total follow-up was 34 months. The mean age was 59 years (54% female). The weight category percentages
were as follows: underweight: 8%; normal: 51%; overweight: 29%; and obese 12%. The multivariate model
showed a higher risk of death for a body mass index,18.5 kg/m2, a neutral risk between 25 and 29.9 kg/m2 and
a protective effect for an index .30 kg/m2. Patients were divided into five categories according to quintiles of
body weight changes during the first year of dialysis: ,23.1%, 23.1 to+0.12%, +0.12 to ,+3.1% (reference
category), +3.1 to +7.1% and .+7.1%. Patients in the lowest quintile had significantly higher mortality,
whereas no negative impact was observed in the other quintiles.
CONCLUSION: These findings suggest that overweight/obesity and a positive body weight variation during the
first year of peritoneal dialysis therapy do not increase mortality in incident dialysis patients in Brazil.
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& INTRODUCTION
Over the last 20 years, the prevalence of overweight and
obesity has increased dramatically in the Brazilian popula-
tion, especially among those aged 20 years and over (1).
Overweight and obesity are known risk factors for highly
prevalent conditions such as type 2 diabetes, hypertension,
cardiovascular diseases, and certain types of cancer (2). In
patients with chronic kidney disease on hemodialysis (HD),
a high body mass index (BMI) is associated with better
survival, whereas a low BMI and weight loss are associated
with increased mortality (3-7). The role of BMI in the
survival of patients undergoing peritoneal dialysis (PD) has
yet to be established; available studies have provided
conflicting results (8-10). Although most physicians do not
consider PD to be the treatment of choice for obese patients,
the percentage of incident patients with high BMIs has risen
progressively in some countries since 1980 (11,12,13).
McDonald et al. evaluated 9,440 PD patients in the
ANZDATA registry and could not show a protective effect
of BMI (11). However, in a prospective study with 45,982 PD
patients, Snyder et al. reported an association between
adjusted mortality and BMI changes over time, with better
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survival among overweight and obese patients until the
third year of PD (14).
The conflicting results regarding the effect of body size on
PD outcomes may relate in part to the inability of BMI to
differentiate between muscle mass and fat tissue (9). Ram
Kumar et al. evaluated the body size and body composition
of 10,140 PD patients (15); the authors concluded that both
factors influence survival in incident patients receiving PD
and that those patients with higher BMIs associated with
normal or high muscle mass exhibited the best survival. In a
recently published paper, Pellicano et al. (16) followed up 60
incident HD (n = 39) and PD (n = 21) patients longitudinally
for 12 months. Using gold standard methods, they found
that dialysis modalities affected changes in total body fat;
extended hours of home HD were associated with the
smallest increase, and PD was associated with the greatest
increase in total body fat, with a significant increase in the
ratio of visceral to subcutaneous fat. Obese patients
experienced greater preservation of total body protein
compared with normal and overweight patients, suggesting
that energy storage as fat mass is of value in the dialysis
patient population.
The Brazilian Peritoneal Dialysis Multicenter Cohort
Study (BRAZPD) is the first large observational PD cohort
study performed in Brazil, and the percentage of obese PD
patients (17) is similar to that of the general population (18).
The aim of this observational study is to determine the
impact of both body size and longitudinal body weight
changes on survival in a cohort of incident PD patients in
the BRAZPD study.
& PATIENTS AND METHODS
Setting and patients
Incident PD patients recruited from 114 dialysis centers
treating more than 10 PD patients each and reporting
monthly to BRAZPD were included in this study. All of the
patients were 18 years or older, remained on PD for at least
90 days and provided complete information on body weight
and height. This study was conducted in accordance with
the Declaration of Helsinki, and all participants provided
written informed consent before enrollment. Details of the
study design and characteristics of the cohort are described
elsewhere (17).
Of the 3,439 incident patients enrolled in the BRAZPD
from December 2004 through October 2007, 1,911 were
eligible for the study, and 1,528 patients were excluded (867
for not completing 90 days of therapy and 661 with more
than 90 days of therapy but lacking either weight or height
data). Out of the 1,528 excluded patients, 1,172 were still
alive and on PD in October 2007, 210 died and 146 dropped
out for reasons other than death as follows: 51 were
transferred to HD, 13 received kidney transplantations, 4
recovered renal function, 13 were transferred to other
clinics, 2 abandoned the study, 6 were lost for other reasons
and 57 had no available data.
Data collection
Data were collected monthly from December 2004
through October 2007. Sociodemographic and clinical data
were evaluated at baseline. Each patient’s medical chart was
thoroughly reviewed by nephrologists who extracted data
pertaining to the underlying renal disease, history of
cardiovascular disease and other comorbid conditions. The
Davies comorbidity score was used to assess the severity of
comorbid conditions (19). The data obtained from the
patients’ charts included the following: sociodemographic
information, chronic kidney disease etiology, hypertension,
and comorbidities. During the follow-up period, body weight
(BW), height, and BMI were evaluated monthly. BMI, defined
as weight in kilograms divided by the square of the height in
meters, was classified according to the World Health
Organization (WHO): underweight (,18.5 kg/m2), normal
(18.5 to 24.9 kg/m2), overweight (25 to 29.9 kg/m2) and
obese (.30 kg/m2). Body weight was measured monthly
without PD fluid in the abdominal cavity. Laboratory
measurements were taken monthly, including creatinine,
urea, potassium, calcium, phosphate, alanine amino-transfer-
ase (ALT), glucose, hemoglobin, albumin, total cholesterol,
and triglycerides, and were determined using routine
methods.
The patients were followed until they received kidney
transplants, recovered renal function, were transferred to
HD, died, or ended their participation in the study.
Statistics
The patients were divided into four groups according to
BMI. The demographic, clinical, and laboratory data were
evaluated for each group. Normally distributed variables
were expressed as means¡SD (unless noted otherwise), and
non-normally distributed variables were expressed as med-
ians and ranges. Differences between the BMI groups were
examined using the Kruskal-Wallis analysis of variance
(ANOVA), followed by a post hoc Dunn’s test for non-
parametric comparisons. A x2 test was used for categorical
variables.
Survival was analyzed with Kaplan-Meier survival curves
and Cox proportional hazards models. The latter were used
to examine survival differences after the analysis had been
adjusted for potential confounding factors (age, gender,
Davies score, and BMI) in incident patients. We used
competing risk analysis to study the influence of BMI on
survival in this cohort of incident PD patients. We also
performed two sensitivity analyses. First, the main analysis
with censoring of follow-up time for the patients (n = 1,615)
who either reached the final follow-up time (n = 1,304) or
ended PD therapy for any reason (drop out not related to
death, n = 311). Second, we reclassified the patients who
ended PD therapy for any reason. Patients who received a
renal transplant, were transfer to HD or recovered renal
function were excluded from the analysis. Survival was
determined after a median follow-up of 13 months (range, 3
to 34 months). Moreover, survival for the entire follow-up
period was analyzed according to the evolution of BW during
the patients’ first year of therapy (n = 1,738). Patients were
divided into five quintiles (,23.1%, 23.1 to +0.12%, +0.12 to
,+3.1% [reference category], +3.1 to +7.1% and .+7.1%)
according to the BW evolution expressed as a percentage
normalized to the ideal body weight calculated from the
Broca formula (ideal BW = (height in cm2 100) for males and
ideal BW = (height in cm 2 104) for females).
Restricted cubic splines were used to evaluate nonlinear
relationships between BMI levels and mortality. This
method has been suggested to offer adequately fit models
and is a good compromise between flexibility and loss of
precision caused by over-fitting a small sample. Statistical
significance was set at p,0.05. Statistical analyses were
performed using Stata software (Version 12.1; Stata Corp.,
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College Station, TX, USA) and SAS statistical software
(Version 9.2 SAS Institute Inc., Cary, NC, USA). As p-values
were not adjusted for multiple testing, they should be
considered descriptive.
& RESULTS
This study included 1,911 incident patients treated by
either Automated PD (APD) or Continuous Ambulatory
Peritoneal Dialysis (CAPD), who started PD between
December 2004 and October 2007 and were followed up
until October 2007. According to the WHO classification, the
BMI distribution of the cohort was as follows: underweight
8%; normal (51%); overweight (29%) and obese (12%).
The mean age of the patients was 59¡16 years old, 54%
were female and 62% were Caucasian. The most common
chronic kidney disease etiology was diabetic nephropathy
(38%). A Davies score greater than 2 was present in 15% of
patients, and the most frequent comorbidities were hyper-
tension (76%) and diabetes (39%). CAPD was the PD
modality for 51% of the patients. The majority of patients
(68%) starting PD were transferred from HD, and the
median time on HD before switching to PD was 7.3 (range,
1.3-60.2) months. Patients were mainly referred to nephrol-
ogists from internists (31%), and 18% of patients were
referred from an emergency unit. In this cohort, 58% of
patients had not received pre-dialysis care, 67% were
illiterate or had ,4 years of schooling and 79% had a
family income less than 5 times the national minimum wage
(, USD$ 7.71/person/day) per month. Only glucose-based
PD solutions were prescribed for all patients (Dianeal,
Baxter Healthcare), and HomechoiceTM (Baxter, Healthcare)
was the cycler used for APD.
There were no significant differences in age, gender,
socioeconomic status, and race distribution when compar-
ing the 1,911 patients in this study and the 1,528 patients
(867 for not completing 90 days of therapy and 661 with
more than 90 days of therapy but lacking either weight or
height data) excluded from the study. Moreover, there were
no significant differences (p = 0.08) among the four BMI
groups when analyzing the 867 patients excluded from the
study for not having completed 90 days of therapy. In this
group of excluded patients, 11.3% were underweight, 48.5%
were normal, 27.2% were overweight, and 13% were obese.
No significant differences in baseline characteristics were
observed between the group of patients who had PD as their
initial renal replacement therapy (RRT) (32%) and the group
of patients who had HD as their first RRT (68%).
Table 1 shows some demographic characteristics and
clinical and laboratory data for the incident PD patients
according to BMI. Overweight patients were older (60¡13
years old; p= 0.001), whereas obese patients were mostly
female (64%; p= 0.001) and exhibited higher systolic (p= 0.001)
and diastolic blood pressures (p= 0.003). The Davies score was
higher than 2 in 18% of the overweight patients and 16% of the
obese patients. Patients who were overweight or obese
presented higher hemoglobin (p= 0.02), glucose (p= 0.001)
and triglyceride (p= 0.007) levels than the other two groups
(normal and underweight). There were no significant differ-
ences in the values of albumin, urea, potassium, calcium,
phosphate, and cholesterol among the BMI groups. For
creatinine, there was a trend towards a significant difference
with higher levels in patients with higher BMIs.
Figure 1 depicts the frequency distribution of BMI in the
incident PD patients, with most patients being normal or
overweight. Figure 2 shows an unadjusted Kaplan-Meier
plot for incident patients according to BMI, with significant
differences in the mortality curves among the different BMI
groups (log rank x2, p,0.0001). The majority (34%) of
patients died due to cardio-vascular causes in all groups.
The most common cause of dropout was not related to the
PD technique in all groups (67.5%).
Figure 3A (univariate and multivariate analysis; conventional
Cox method), Figure 3B (univariate and multivariate analysis;
competing Cox method), and Figure 4 (Spline curve) show the
Cox proportional hazard for the incident patients, according to
BMI. In a conventional Cox multivariate analysis (Figure 3A),
both BMI 25-29.9 kg/m2 (HR = 0.74, CI: 0.56 to 0.98, p,0.05) and
BMI.30 kg/m2 (HR = 0.63, CI: 0.42 to 0.95, p,0.05) reflected
protection from mortality risk, whereas BMI,18.5 kg/m2
reflected a higher mortality risk (HR = 1.72, CI: 1.15 to 2.55,
p,0.001). Figure 3B indicates that in the multivariate Cox
analysis with competing risks, BMI,18.5 kg/m2 (HR = 1.46
(0.98-2.1), p= 0.05) and BMI 25-29.9 kg/m2 (HR = 0.78 (0.59-
1.04), p= 0.08) were not significant, whereas BMI.30 kg/m2
Table 1 - Characteristics of incident patients with PD by underweight (,18.5 kg/m2), normal (18.5 to 24.9 kg/m2),
overweight (25 to 30 kg/m2), and obese (.30 kg/m2).
Under-weight N=159 Normal N=985 Over-weight N=547 Obese N=220 p-value
Sex female (%) 68% 55% 46% 64% 0.001
Age (years) 55¡21 57¡17 60¡13 59¡12 0.001
Systolic BP (mm Hg) 132¡23.5 138.9¡24 141.7¡25.5 144.8¡26.6 0.001
Diastolic BP (mm Hg) 81¡14 83.2¡14.2 85¡14 85¡14 0.003
S-albumin (g/L) 3.7¡1.4 4.2¡1.2 4.3¡2.4 4.2¡1.2 NS
S-creatinine (mg/dL) 6.8¡3.1 7.5¡4.3 7.7¡4.6 8.2¡4.8 0.07
S-urea (mg/dL) 109.6¡47 116.3¡48 117¡48 115.7¡44 NS
Hemoglobin (g/L) 10.4¡2.3 10.4¡2.9 10.8¡2.6 10.5¡2.1 0.02
Phosphate (mg/dL) 4.9¡1.9 5.5¡1.8 5.1¡1.8 5.4¡3.3 NS
Calcium (mg/dL) 8.5¡2.2 8.4¡3.5 8.3¡2.4 8.38¡2.4 NS
Potassium (mEq/L) 4.4¡1.1 4.6¡1 4.7¡2.4 4.5¡0.9 NS
Glucose (mg/dL) 106¡67 115¡76 122¡78 127¡75 0.001
Triglycerides (mg/dL) 143¡86 172¡101 209¡166 223.2¡97 0.007
Tot cholesterol (mg/dL) 190.8¡55 190¡63 184¡61 199.9¡62 NS
Davies score: 0.03
0 27% 22% 16% 16%
1-2 62% 64% 65% 67%
.2 11% 14% 18% 16%
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reflected protection from mortality risk (HR = 0.67 (0.45-0.99),
p= 0.04). Figure 4 shows the Spline Cox proportional hazard
based on baseline BMI; the model is adjusted for age and
gender. The curve depicts the relationship between log Hazard
Ratios and BMI levels in incident PD patients, demonstrating
that low BMI is associated with higher mortality and that high
BMI is associated with lower mortality.
Table 2A depicts the Cox proportional hazard for the
evolution of body weight during the first year of PD in
incident patients. The patients were divided into five
categories according to the quintile distribution: ,23.1%,
23.1 to +0.12%, +0.12 to,+3.1% (reference category), +3.1 to
+7.1% and .+7.1%. There was significantly higher mortality
(HR = 2.10, p,0.001) in the lowest quintile (-3.1%), whereas
no impact was observed in the 3.1 to +0.12% quintile when
compared to the reference category. In patients who gained
+3.1 to +7.1% or .+7.1%, no impact was observed when
compared to the reference weight. The patients who gained
weight (.+7.1%) had an HR = 0.81 with a narrow CI 0.54-
1.24 in relation to the reference weight. In a multivariate Cox
proportional hazard analysis (Table 2B), the lowest quintile
(-3.1%) was associated with higher mortality (HR = 1.94,
p,0.0001) when compared to the reference weight, whereas
no impact was observed in the other quintiles.
There were no differences in the frequencies of categories
of BW evolution during the first year of therapy among the
baseline BMI groups in 1,738 incident PD patients. BW gain
during the first year was similarly distributed among the four
groups (underweight, 42%; normal, 42%; overweight, 38%;
and obese, 37%). Thirty-four percent of patients were more
than 65 years of age. The younger and older (.65 years of
age) patients presented similar underweight (7.8% vs. 8.3%),
overweight (27.5% vs. 31.4%), and obesity (12% vs. 11.3%)
distributions (p= 0.31).
Figure 1 - Histogram of BMI (kg/m2) for all PD patients at baseline.
Figure 2 - Unadjusted Kaplan-Meier survival curves for incident PD patients and all-cause mortality, according to BMI levels.
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In this large observational study of incident PD patients
performed in Brazil, we demonstrated that a higher BMI
(overweight and obese) is not associated with higher
mortality when compared to normal (neutral risk) or
underweight (higher risk of death). In a multivariate Cox
proportional hazard analysis, the evolution of BW in the
lowest quintile was associated with a higher mortality when
compared to the reference, whereas no negative impact was
observed in the other quintiles.
In the last 20 years, the number of people with obesity has
increased dramatically in Brazil (www.ibge.gov.br, accessed
in November 2007) (18). The BRAZPD is the first large
observational PD study performed in this country, and the
percentage of PD patients with obesity is similar to that of
the general population (18).
In the general population, obesity is considered unhealthy;
obesity is associated with a higher risk of cardiovascular
disease (20), diabetes (21), cancer (22), kidney disease (23,24),
and other comorbidities, and it correlates with mortality. It is
important to note that while obesity has been shown to be a
Figure 3 - A) Univariate and multivariate Cox regressions for predictors of all-cause mortality in incident patients. B) Univariate and
multivariate Cox regressions for predictors of all-cause mortality in incident patients with competing risk analysis. Hazard Ratios (HR)
for all-cause mortality [and 95% confidence intervals (CI)] for patients with BMI,18.5 kg/m2, BMI 25 to 29.9 kg/m2 and BMI.30 kg/m2.
Patients with BMIs ranging from 18.5 to 24.9 kg/m2 were considered the reference. p-value, significance level ,0.05. The models are
adjusted for potential confounders, i.e., baseline comorbidities (cardiovascular disease (CVD) and diabetes mellitus (DM)), automated
peritoneal dialysis or continuous ambulatory peritoneal dialysis, renal replacement therapy, and calendar year (CY) (2005, 2006 and
2007).
Figure 4 - In the left Y-axis, restricted spline curve showing the age, gender and comorbidities-adjusted Hazard ratios and 95%
confidence intervals (CI) (dashed lines) for all-cause mortality associated with BMI in 1,911 incident PD patients. The model is plotted as
restricted cubic splines with four knots. Log HR, Log transformed Hazard ratio; 95% CI, lower and upper 95% confidence intervals,
respectively. P for linearity = 0.01.
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risk factor for mortality in the general population with more
than 10 years of follow-up (25), CVD mortality in the dialysis
patient population, even after stratification, is 10 to 20 times
higher than in the general population (26). Consequently, the
follow-up time in studies evaluating dialysis patients and the
general population should be different (27). However, obesity
may be protective against mortality under several conditions,
including in elderly and HD patients and in cases of chronic
obstructive pulmonary disease, acquired immunodeficiency
syndrome and rheumatoid arthritis (3,28). Obesity has also
been reported to have a protective effect for patients with
congestive heart failure and geriatric patients, i.e., populations
with extraordinarily high mortality rates (28).
Exploring the causes and consequences of this epidemio-
logical observation for obesity in PD patients may enhance
our insights into similar paradoxes observed for other
conventional risk factors, such as blood pressure, serum
cholesterol and homocysteine (23,29-33). It is important to
note that in this study adverse clinical characteristics are
readily observed in the epidemiological profile of the
overweight and obese PD patients, i.e., higher age, increased
hypertension, diabetes and higher Davies comorbidity
scores. However, in this study, obesity is still not associated
with higher mortality risk. Similar results have been observed
by Chazot et al. (3) in a cohort of 5,592 HD patients; despite
increased comorbidities, overweight and obese HD patients
carried a significantly lower mortality risk than those HD
patients with normal and lower BMI ranges.
Agarwal et al. (34) evaluated the relationship between
blood pressure (BP) control and BMI in HD patients. They
observed that a lower BMI was associated with worse BP
control and higher mortality during patients’ first two years
on dialysis, justifying this higher mortality to the patients
with greater severity. However, no time-dependent analysis
of BP, body composition or inflammation was evaluated
(35). These findings that higher mortality is associated with
lower BMI are in agreement with our results. However, in
our study, the overweight/obese patients did not have
higher mortality, even though they presented with higher
Davies comorbidity scores than the lower BMI group.
De Mutsert et al. (36) evaluated incident PD patients
selected from the NECOSAD study and followed them for
five years; they found that obese incident PD patients did
not have worse survival compared with normal BMI
incident PD patients. In the same study, PD patients with
a low BMI had a two-fold increased mortality risk. Our
results also demonstrate higher mortality in patients either
presenting lower BMI (,18.5 kg/m2) or a longitudinal
weight loss of .-3.1 kg during the first year of therapy.
A recent study involving the NECOSAD database
examined the differences between the impact of BMI on
mortality in HD and PD patients, stratified by age (.65
years and ,65 years). They found that in patients younger
than 65 years of age, obesity was associated with higher
mortality (37). This study presents relevant differences in
relation to our study: first, the percentage of older patients
was higher (47.3%) than in our study (34%); second, BMI
was evaluated only at baseline, and there was no informa-
tion about the variation of the BMI over time. Pellicano et al.
(16), in a longitudinal study evaluating BMI, stratified the
patients by age and did not observe differences between age
groups. In our study, the prevalences of malnutrition and
overweight/obesity in patients younger and older than 65
years were the same; like the majority of the studies, we
adjusted for age, and no impact was observed.
In this study, mortality curves adjusted for age, gender,
and Davies score indicated that obesity does not increase
mortality for incident PD patients (HR = 0.67, CI: 0.47 to
0.95, p = 0.02). Pellicano et al. have hypothesized that a
higher BMI is protective because of increased energy storage
as total body fat, which could lead to relative preservation
of lean body mass (16). In their study, obese patients
experienced greater preservation of total body protein when
compared with normal and overweight patients. Recently,
Kalantar-Zadeh et al. (7) raised the question, ‘‘what is better:
fat or muscle?’’, and concluded that body fat is a protective
factor for patients on hemodialysis.
In our study, BW gain during the first year was similarly
distributed among the four groups. However, a BW loss
.3.1% (first quintile) during the first year of treatment was
associated with significantly increased mortality when
compared to the reference, whereas no impact was observed
in the other quintiles. Our findings are in agreement with
the study by Kalantar-Zadeh et al. (32), which examined a
cohort of 54,535 MHD patients in the United States over two
years. The authors found that for each BW loss category
below -1%, there was a significant increase in patient death.
Obesity, including morbid obesity, was associated with
better survival and reduced cardiovascular death, even after
accounting for changes in BMI and laboratory values. Over
Table 2 - Univariate (A) and multivariate (B) Cox regressions for predictors of all causes of mortality in according to the
evolution of body weight during the first year of PD treatment.
A- Univariate analysis – all causes of mortality.
Variable Hazard Ratio 95% CI x2 p-value
,23.1%, vs 0.12 to ,3.1% 2.10 1.47-3.02 4.06 ,0.001
23.1 to ,0.12% vs 0.12 to ,3.1% 1.18 0.81-1.77 0.84 0.41
+3.1 to ,+7.1% vs 0.12 to ,3.1% 1.08 0.73- 1.61 0.41 0.68
.+7.1%. vs 0 to 0.12 to ,3.1% 0.85 0.56-1.29 0.74 0.46
B- Multivariate -all cause of mortality adjusted for age, gender, CVD, DM, APD/CAPD, RRT and calendar year
,23.1%, vs 0.12 to ,3.1% 1.94 1.35 - 2.8 3.59 ,0.001
23.1 to ,0.12% vs 0.12 to ,3.1% 1.29 0.86 - 1.95 1.24 0.21
+3.1 to ,+7.1% vs 0.12 to ,3.1% 1.10 0.74 - 1.63 0.47 0.63
.+7.1% vs 0 to 0.12 to ,3.1% 0.81 0.54 - 1.24 0.94 0.34
Indicated are Hazard Ratios (HRs) for all-cause mortality [and 95% confidence intervals (CI)] for patients with weight evolution ,23.1%, 23.1 to ,0.12%,
+3.1 to ,+7.1% and .+7.1%. The patients with weight evolution between 0.12 to ,3.1% were considered as reference. A p-value with significance level
,0.05. The models adjust for potential confounders i.e. baseline comorbidities (cardiovascular disease (CVD), and diabetes mellitus (DM)), automated
peritoneal dialysis or continuous ambulatory peritoneal dialysis, renal replacement therapy, calendar year (CY) (2005, 2006, 2007).
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time, progressively worsening weight loss was associated
with poor survival, whereas weight gain showed a tendency
toward decreased cardiovascular death.
Chazot et al. (3) have also demonstrated that BW variation
during the first year of HD treatment is associated with
patient survival, reinforcing the importance of nutrition in
this setting. Our results, based on a large cohort of incident
PD patients, corroborate the findings reported by Chazot et
al. (3) and give support to the recently published results by
Pellicano et al. (16) with both incident PD and HD patients.
Our incident PD patients who gained weight did not
present increased mortality when compared to the refer-
ence. However, a BW loss .3.1% (first quintile) during the
first year of treatment was associated with significantly
increased mortality, whereas the second quintile (23.1 to
0.12%) had no significant reduction in survival.
As a matter of a fact, there are more review articles than
original papers on the BMI and mortality theme, especially in
the PD field. Moreover, these articles report on populations
from North America, Europe, Asia and Australia-New Zealand
but not on Latin American populations. Brazil was settled by
the Portuguese, and the Brazilian ethnicity is primarily mixed.
Therefore, some of the positive aspects of this paper are its
originality, as it is characterized by Brazilian incident PD
patients and a longitudinal approach to body changes.
As far as we know, this is the second study in PD patients
evaluating changes in BMI over time. Although this is an
observational study, the large number of patients and
statistically significant findings indicate that a BMI.30 kg/
m2 does not increase the mortality risk for incident patients
on PD. Despite the negative selection (only 32% of patients
actually chose PD as an RRT modality), as most patients were
either transferred from HD or started PD as late referrals and
showed a great deal of poor social indicators, the clinical
outcomes of the BRAZPD cohort (38) are not different from
those reported elsewhere (39,40). However, this observa-
tional study does not provide an explanation for the effect of
BMI, and future prospective interventional studies may lead
to a clarification of the ‘‘obesity paradox’’, adding substan-
tially to the strength of our findings.
Our study has some limitations. First, we relied on
registry data, and the limitations of this study model are
well known. Second, we lack data on residual renal function
and D/P creatinine as potential modifiers of outcomes.
Third, the fact that BMI does not measure body composition
is an inherent limitation. Finally, the short median follow-up
time and lack of adjustment for smoking are additional
study limitations. It is important to note that studies
evaluating body weight longitudinally in dialysis patients
have reported body weight changes up to 12 months, as we
did in our study. Our total follow-up time was 34 months.
It is of utmost importance for us to stress that this study
does not suggest that dialysis patients should become obese.
Our findings reflect routine dialysis practice where over-
weight/obese incident PD patients seem to have a protective
survival advantage. Therefore, there is a compelling need to
design studies to understand the possible mechanisms that
lead to a protective effect of higher BMI in dialysis patients.
The study designed, performed and published by
Pellicano et al. (16) with a small number of patients serves
as timely support to our novel finding, as they suggest that
energy storage as total body fat is of value in the dialysis
population. A novel observation from the results of the large
cohort (BRAZPD) with incident PD patients in this study is
that positive BW variation during the first year of therapy
does not have a significant impact on mortality, allowing us
to suggest that both overweight/obesity and BW gain
during the first year of therapy do not increase mortality in
incident PD patients in Brazil.
The following centers participated in the Brazilian Peritoneal
Dialysis multicentric study and contributed to the preparation
of this paper: Ameneg, Associac¸a˜o Hospital Bauru, Biocor
Hospital Doenc¸as Cardiolo´gicas, Casa de Sau´de e Mat. Nossa
Sra. Perpe´tuo do Socorro, CDR Curitiba, CDR Goiania, CDR
Imperatriz, CDR Sa˜o Jose´ Pinhais, CDTR - Centro Dia´lise
Transplante Renal, Centro Nefrologia Tereso´polis, Centro
Nefrolo´gico Minas Gerais, Centro Tratamento Doenc¸as Renais
Joinville, Centro Tratamento Renal Zona Sul, Clinef Rio de
Janeiro, Clinepa Clı´nica de Nefrologia Da Paraiba, Clines,
Clinese, Clı´nica do Rim do Carpina, Clı´nica Evange´lico S/C
Ltda., Clı´nica Nefrologia de Franca, Clı´nica Nefrologia Santa
Rita, Clı´nica Nefrolo´gica Sa˜o Gonc¸alo, Clı´nica Paulista
Nefrologia, Clı´nica Renal Manaus, Clı´nica Senhor do Bonfim,
Clı´nica Senhor do Bonfim Ltda. Filial, Clı´nica Tratamento Renal,
Cuiaba - Cenec, Clire Clı´nica Doenc¸as Renais, FAMESP
Botucatu, Unicamp - Universidade Estadual de Campinas,
Hospital Clı´nicas FMRPUSP, Fundac¸a˜o Civil Casa Mis Franca,
Fundac¸a˜o Instituto Mineiro Est. Pesq. Nefrol, Gamen Rio de
Janeiro, GDF Hospital de Base, Histocom Sociedade Civil Ltda,
Hospital Universidade Prof. Edgard Santos, Hospital
Beneficencia Portuguesa Pernambuco, Hospital Cidade Passo
Fundo, Hospital Clı´nica Universidade Federal Goia´s, Hospital e
Maternidade Angelina Caron, Hospital Evange´lico Vila Velha
ES, Hospital Geral Bonsucesso, Hospital Geral de Goiania,
Hospital Infantil Joana de Gusma˜o, Hospital Sa˜o Joa˜o Deus,
Hospital Sa˜o Jorge, Hospital Sa˜o Jose do Avai, Hospital Sa˜o
Vicente de Paula - Joa˜o Pessoa, Hospital Sa˜o Vicente De Paulo,
Hospital Servidor do Estado Ipase, Hospital Universidade
Presidente Dutra MA, Hospital Universita´rio Antoˆnio Pedro,
Hospital Vita Volta Redonda S/A, IAMSPE Sa˜o Paulo, IMIP,
Instituto Capixaba Doenc¸as Renais, Instituto Capixaba Doenc¸as
Renais Cariacica, Instituto Capixaba Doenc¸as Renais Serra,
Instituto do Rim de Fortaleza, Instituto do Rim de Marilia,
Instituto do Rim do Parana S/C Ltda., Instituto do Rim Santo
Antoˆnio da Platina, Instituto Hemodia´lise de Sorocaba, Instituto
Medicina Nuclear Endocrina, Instituto Nefrologia de Mogi das
Cruzes, Instituto Nefrologia de Suzano, Instituto Nefrologia
Souza e Costa, Instituto Urologia e Nefrol Barra Mansa,
Instituto Urologia e Nefrol Sa˜o Jose´ do Rio Preto,
MEDSERVSP, Nefrocentro, Nefroclı´nica Caxias do Sul,
Nefroclı´nica Foz do Iguac¸u, Nefroclı´nica Uberlandia, Nefron
Clı´nica Natal, Nefron Contagem, Nephron Pelotas, Nephron
Sa˜o Paulo, Nu´cleo Nefrologia Belo Horizonte, Pro Nephron,
Prorim Campos dos Goitacazes, PUC Porto Alegre, Renalcare
Servic¸os Me´dicos Ltda, Renalcor Angra dos Reis, Renalcor Rio
de Janeiro, Renalvida, Rien Rio de Janeiro, Santa Casa de
Adamantina, Santa Casa de Jau´ - UNEFRO, Santa Casa de
Marı´lia, Santa Casa de Ourinhos, Santa Casa de Santo Amaro,
Santa Casa de Sa˜o Jose´ dos Campos, Santa Casa de
Votuporanga, Servic¸o de Nefrologia de Ribeira˜o Preto, UERJ -
Hospital das Clı´nicas da Universidade Estadual do Rio de
Janeiro, Uni Rim Joa˜o Pessoa, Unidade Nefrologia Assis,
Unirim Unidade de Doenc¸as Renais, UNIRIM Unidade Renal
do Porta˜o, UNTR Unidade Nefrologia Transplante.
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